Otsuka said to eye $300M deal for Claris injectables; Eisai sues insurer over whistleblower claim;

@FiercePharma: Pfizer slashes Viagra prices in Canada to compete with new generics. Cut = 25%. News | Follow @FiercePharma

> Claris Lifesciences is said to be in talks to sell its injectables business to Japan-based Otsuka Pharma for up to $300 million. Report

> Eisai has sued Zurich American Insurance for denying a claim stemming from a whistleblower lawsuit field by a former sales rep. Report

> Hetero India and Neopharma's joint venture, Nexgen Pharma, plans to sell branded generics in the United Arab Emirates, aiming for 100 products by 2016. Report

> Oregon Health & Science University School of Medicine plans to recommend that researchers no longer accept speaking fees from drugmakers. Report

> India's Lupin launched its version of the Abbott Laboratories' ($ABT) cholesterol pill Tricor. Report

> The American Academy of Pediatrics recommended that doctors routinely prescribe "morning after" contraception to teens in case they need it; the drugs aren't available over the counter to patients under 17. Report

Medical Device News

 @FierceMedDev: Illumina gains legal means to keep fighting a patent claim against Complete Genomics. News | Follow @FierceMedDev

 @MarkHFierce: Volcano Corp., a rumored acquisition target, has itself acquired a company. More | Follow @MarkHFierce

 @DamianFierce: Innovent Biologics is moving into WuXi PharmaTech's backyard with a new Chinese plant. Report | Follow @DamianFierce

> Sorin commits $5.4M to percutaneous mitral valve replacement startup. Article

> Report: Baxter close to paying $4B for dialysis rival Gambro. More

> Analyst: St. Jude's woe is good news for Boston Scientific. News

Biotech News

 @FierceBiotech: Trending on FierceBiotech.com: Blockbuster buzz: 15 top therapies in late-stage development. Special Report | Follow @FierceBiotech

 @JohnCFierce: AstraZeneca, Pfizer partner on $100M drug research collaboration project. Report | Follow @JohnCFierce

 @RyanMFierce: Averting the next bapi bust? J&J exec prescribes new approach to Alzheimer's drug development. Story | Follow @RyanMFierce

> J&J preps case for quick FDA approval of new TB drug. News

> No, Minister: Disgruntled Novartis threatens to steer R&D away from U.K. Story

Biotech IT News

> Eisai's H3 Bio leans on bioinformatics as cancer researcher expands. Report

> NIH taps Northrop Grumman for $30M bioinformatics project. Article

> J&J exec prescribes adaptive approach to Alzheimer's drug development. Story

CRO News

> U.K. wants CRO input on clinical trial reforms. Report

> QPS boosts Phase I capabilities in Netherlands. News

> Innovent targets WuXi with biologics plan. Story

> ShangPharma stumbles over increased costs in Q3. Article

And Finally... Ritalin and other stimulant drugs cut the crime rate in adults with ADHD, a study found. Report

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.